Emily Lebow, MD
@EmilyLebow
Followers
288
Following
709
Media
4
Statuses
65
Radiation onc @PennMedicine | Brain tumor research | Mom 👧🏻👧🏻 | Alum of @MSK_RadOnc @Harvardmed @Penn
University of Pennsylvania
Joined June 2021
Always a highlight of @ASTRO_org Meetings, the Awards ceremony🔥 Because we like to celebrate our community🥳 Huge shoutout to classmate, friend, role model, and mentoring force Helen Shih of MGH/MGB👏👏👏 (now she just needs to join #SoMe‼️) #ASTRO25
@DKirschMDPhD
1
7
33
Special thanks to @JHGLab, @LiaHalaszMD , @KylieKangMD, Luke Pike. @RachelJimenezMD, @DrWilliamHwang, @BrandonMahal, @MinaBakhtiar, @AmyWisdom8, @ShervinTabrizi, @theabzlab, @EJVaios, @DanielKimMD, and many others who contributed to the nomination 🙌 @HarvardRadOnc
0
0
2
I was privileged to nominate Dr Helen Shih for the ASTRO Mentorship Award and thrilled to see her honored this year along side Drs Gibbs and Yahalom🌟 She’s been an incredible mentor to me since med school in 2016, shaping my path in rad onc and inspiring me to mentor others
1
0
3
Congratulations to Iris Gibbs, MD, FASTRO; Helen Shih, MD, MS, MPH, FASTRO; & Joachim Yahalom, MD, FASTRO on their 2025 ASTRO Mentorship awards!! They will be recognized at #ASTRO25 in San Francisco. @StanfordRadOnc @MassGeneralNews @MSK_RadOnc
https://t.co/TIGyGv8Zfq
1
13
48
#ASCO25: @StephenBagleyMD on CAR T cell for glioblastoma: “The treatment changed the trajectory of their disease.” Now in @NatureMedicine and on the @ASCO stage today. Abstract 102. @DrORourke2
0
5
9
The @NCCN Foundation has announced MCC member, Kathryn Tringale, MD, MAS, as a 2025 Young Investigator Award recipient. This award recognizes her impact on cancer care through neuroimaging and biomarker research on neurotoxicity after CAR T-cell therapy: https://t.co/5b5zyPjgXH.
1
3
11
#CARTcells for #DIPG #DMG clinical trial (1st arm) results are out today. Full Tweetorial coming, but first want to share the story of a patient whose #DIPG has disappeared for over 3 years. It is a milestone and moment of hope on a journey filled with so much grief. “There’s a
30
159
622
Thanks, @HenningWillers! Great to present promising options for pts with locally advanced #lungcancer who are ineligible for chemoRT. @MSKCancerCenter @MSK_RadOnc
1/2 Promising outcomes of combining #radiotherapy and durvalumab without chemo in LA-NSCLC. PFS associated with PD-L1. Wonder if there is a path for personalized therapy where chemo can be dropped in high PDL1? #ASTRO24
0
0
4
🧠☢️⚡️New in @JAMAOnc from @MSKCancerCenter #radonc grad Dr @EmilyLebow w/ Dr @yaoyu_md: Antibody-drug conjugates given concurrently with Stereotactic #radiotherapy #SRS were associated with ⬆️risk of symptomatic #radiation necrosis. More details here: https://t.co/F2Q0i1Zoog
0
6
24
🫁☢️New in @jitcancer from @MSKCancerCenter #radonc and @DanaFarber: This analysis of outcomes to #chemoradiation & #durvalumab in stage III non-small cell #lungcancer #NSCLC suggests that tumor aneuploidy is a promising predictive biomarker. #lcsm ➡️ https://t.co/GrrTZCp9OU
0
4
12
Just out in @JAMAOnc - important data on risk factors for #brainmet necrosis with concurrent ADC + SRS: understanding sequencing essential as CNS outcome data emerge @MSK_RadOnc @MSK_DeptOfMed @MSKNeurosurgery @EmilyLebow @yaoyu_md @Dr_Luke_Pike @Dr_N_Moss
In this study, giving an antibody-drug conjugates (T-DXd, T-DM1, SG) concurrently with stereotactic radiotherapy was associated w/ higher risk of radiation necrosis. The absolute risk was low for small lesions, but increased rapidly w/ volume & prior RT.
0
9
29
Happy to share our work on SRS with concurrent ADCs, now out @JAMAOnc! In this study, led by @EmilyLebow, we investigated the risk of symptomatic radiation necrosis for pts receiving SRS and brain metastases. ADCs included T-DXd, T-DM1, and SG. (1/n) https://t.co/dplp1nJKmW
jamanetwork.com
This cohort study investigates whether brain metastases that manifest after stereotactic radiotherapy with concurrent antibody-drug conjugates are associated with an increased risk of symptomatic...
3
17
57
In this study, giving an antibody-drug conjugates (T-DXd, T-DM1, SG) concurrently with stereotactic radiotherapy was associated w/ higher risk of radiation necrosis. The absolute risk was low for small lesions, but increased rapidly w/ volume & prior RT.
2
57
141
In @FrontiersIn we highlight the potential of #ctDNA to guide personalized therapy for patients with #lungcancer Thank you @NateraOncology, @Natera, @YoninaMG , Bob Li, @danielrgomez44, Andreas Rimner & many more at @MSK_RadOnc @MSKCancerCenter! 🔗 https://t.co/npLr08ugOU
0
2
24
🎙 SBRT for #sarcoma 🫁metastases achieved high rates of local control w/ low toxicity❗️🚨@OncoAlert @RadiotherapyOn1 📌retro single 🏥study 🥇🎯: Local failure 📊RESULTs 👉66 👥w/ 95 🫁metastases 👉local failure at 12 & 24 m 3.1% &7.4% 👉OS at 12 & 24 m 74% & 49%
1
22
66
☢️🫁 New in @RadiotherapyOn1 from Dr @EmilyLebow: We observed excellent long-term disease control with #SBRT for #sarcoma pulmonary metastases & potential for prolonged survival particularly among pts with oligometastatic disease at the time of SBRT. https://t.co/pGxHFDzvcx
0
21
52
🚨A #radonc away rotation @MSKCancerCenter means a month to explore the best of NYC: our cancer center, outstanding faculty, & what residency in the city that never sleeps really feels like🚕🌃🥯☕️ For July-December: Apply🔜via VSLO For June: 📩 medstudent@mskcc.org #match2024
1
8
29
It's a Match! Welcome to @MSKCancerCenter #radonc!! 🥳 🙌Kathryn Hockemeyer MD, PhD 🙌Gideon Haber, MD 🙌Elisa Liu, MD 🙌Revathi Ravella, MD 🙌Alexander Terry, MD 🙌Shoshana Rosenzweig, MD We're excited to have you join us in New York! #Match2023 #radoncMatch2023
1
14
126
New from former @MSKCancerCenter #proton Dr @AnnaLeeMDMPH with @imrtlee: Compared with previous reports of photon-based #reirradiation, pts are living longer with aggressive proton-ReRT; however, surviving pts remain at risk of early & late complications. https://t.co/6qP1fE32Kc
0
13
25
Study by @EmilyLebow, Narek Shaverdian & colleagues find high TMB status was associated with improved PFS after definitive chemoradiation & adjuvant durvalumab in those with unresectable locally advanced #NSCLC 🫁 #OpenAccess study in @JAMANetworkOpen ➡️ https://t.co/RBO125MnKX
0
8
13